ShareCompartir
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Notice to Readers: Update: Vol. 47, No. 9
In the report, "Human Exposure to Brucella abortus Strain RB51 --- Kansas, 1997," the sixth paragraph of the Editorial Note (page 174) mentioned efforts by CDC's Special Bacteriology Reference Laboratory to develop a polymerase chain reaction assay for detection of human RB51 infection. However, currently no validated routine test is available to monitor infections associated with exposure to the RB51 vaccine strain. Exposure to RB51 does not elicit a measurable antibody response; therefore, serology cannot provide an indicator of infection. Persons seeking assistance in identifying Brucella spp. or serologic monitoring of exposed persons should contact their state health departments or the CDC Bacterial Special Pathogens Branch at telephone 404-639-1711.
Postexposure prophylaxis is recommended for persons at high risk. A high-risk exposure is defined as 1) having direct personal exposure to Brucella (e.g., sniffing bacteriologic cultures, direct skin contact, pipetting by mouth, inoculation, or spraying into the eyes, nose, or mouth), 2) performing work on an open bench (i.e., outside of biosafety level 3 containment equipment) with an open culture plate containing a Brucella isolate or being in close proximity to such work (e.g., across an open bench top or within 5 feet), or 3) presence in the laboratory during any procedure conducted on a Brucella isolate that might result in generation of aerosolized organisms and inhalational exposure (e.g., vortexing or catalase testing).
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
